Autolus Therapeutics PLC
AUTL2.375USD
+0.025+1.06%
交易中 （美东）报价延迟15分钟
632.05M总市值
亏损市盈率 TTM
关于 Autolus Therapeutics PLC 公司
Autolus Therapeutics plc 是一家英国临床阶段生物制药公司，致力于开发用于治疗癌症和自身免疫性疾病的程序化 T 细胞疗法。该公司专注于嵌合抗原受体 (CAR)-T 细胞疗法。该公司利用一套专有和模块化的 T 细胞编程技术，设计出有针对性的、可控的、高活性的 T 细胞疗法候选产品，旨在识别靶细胞、破坏其防御机制并消灭这些细胞。该公司拥有一系列用于治疗血液系统恶性肿瘤、实体瘤和自身免疫性疾病的候选产品。其产品线包括 obe-cel (FELIX)、obe-cel (ALLCAR19)、obe-cel (CAROUSEL)、AUTO1/22 (CARPALL)、AUTO4 (LibrA T1)、AUTO6 (MAGNETO)、AUTO5、AUTO8 (MCARTY) 和 AUTO9。 AUTO4 和 AUTO5 是两种程序化 T 细胞疗法，用于治疗针对 T 细胞受体β 常数 (TRBC) 1 和 TRBC 2 的外周 T 细胞淋巴瘤。
公司简介
公司代码AUTL
公司名称Autolus Therapeutics PLC
上市日期Jun 22, 2018
CEODr. Christian Martin Itin, Ph.D.
员工数量647
证券类型Depository Receipt
年结日Jun 22
公司地址The Mediaworks
城市LONDON
上市交易所NASDAQ Global Select Consolidated
国家United Kingdom
邮编W12 7FP
电话442038296230
网址https://www.autolus.com/
公司代码AUTL
上市日期Jun 22, 2018
CEODr. Christian Martin Itin, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. Robert (Rob) Dolski
Mr. Robert (Rob) Dolski
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chairman of the Board
Chairman of the Board
--
--
Mr. John Edward Berriman
Mr. John Edward Berriman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William D. (Bill) Young, Ph.D.
Mr. William D. (Bill) Young, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. Robert (Rob) Dolski
Mr. Robert (Rob) Dolski
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chairman of the Board
Chairman of the Board
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
暂无数据
地区USD
名称
营收
占比
United States
8.98M
100.00%
United Kingdom
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 6月27日 周五
更新时间: 6月27日 周五
持股股东
股东类型
持股股东
持股股东
占比
BioNTech SE
12.52%
Syncona Investment Management Limited
11.55%
Wellington Management Company, LLP
10.18%
Clarus Ventures, LLC
7.70%
Deep Track Capital LP
6.71%
Other
51.34%
持股股东
持股股东
占比
BioNTech SE
12.52%
Syncona Investment Management Limited
11.55%
Wellington Management Company, LLP
10.18%
Clarus Ventures, LLC
7.70%
Deep Track Capital LP
6.71%
Other
51.34%
股东类型
持股股东
占比
Investment Advisor
30.97%
Hedge Fund
22.24%
Investment Advisor/Hedge Fund
21.92%
Corporation
12.52%
Venture Capital
7.96%
Sovereign Wealth Fund
5.64%
Holding Company
5.55%
Private Equity
1.74%
Research Firm
0.57%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
230
290.52M
109.16%
+36.32M
2025Q1
233
278.22M
104.55%
+21.95M
2024Q4
238
276.47M
103.89%
+17.40M
2024Q3
228
281.50M
105.79%
+29.96M
2024Q2
230
250.31M
94.10%
+23.29M
2024Q1
222
248.02M
93.27%
+78.60M
2023Q4
195
154.83M
95.00%
+7.81M
2023Q3
172
154.39M
98.35%
+17.90M
2023Q2
174
153.07M
97.70%
+21.18M
2023Q1
175
149.40M
95.88%
+11.90M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BioNTech SE
33.33M
12.52%
+33.33M
--
Feb 13, 2024
Syncona Investment Management Limited
30.73M
11.55%
+30.73M
--
Sep 30, 2024
Wellington Management Company, LLP
27.09M
10.18%
+1.75M
+6.89%
Mar 31, 2025
Clarus Ventures, LLC
20.49M
7.7%
--
--
Mar 31, 2025
Deep Track Capital LP
17.85M
6.71%
+3.63M
+25.53%
Mar 31, 2025
Syncona Portfolio Ltd
16.64M
6.25%
--
--
Mar 31, 2025
MAK Capital One, LLC
15.41M
5.79%
+15.41M
--
Jun 17, 2025
Qatar Investment Authority
15.00M
5.64%
--
--
Mar 01, 2025
PPF Group N.V.
14.78M
5.55%
+170.00K
+1.16%
Oct 24, 2024
Armistice Capital LLC
11.00M
4.13%
+1.80M
+19.57%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.95%
Invesco NASDAQ Future Gen 200 ETF
0.59%
ALPS Medical Breakthroughs ETF
0.41%
Tema Oncology ETF
0.31%
iShares Health Innovation Active ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.04%
SPDR S&P International Small Cap ETF
0.02%
Fidelity Fundamental Small-Mid Cap ETF
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.95%
Invesco NASDAQ Future Gen 200 ETF
占比0.59%
ALPS Medical Breakthroughs ETF
占比0.41%
Tema Oncology ETF
占比0.31%
iShares Health Innovation Active ETF
占比0.09%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
Invesco Nasdaq Biotechnology ETF
占比0.05%
iShares Biotechnology ETF
占比0.04%
SPDR S&P International Small Cap ETF
占比0.02%
Fidelity Fundamental Small-Mid Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
